EVOS

For operating partners and portfolio managers

Know which companies will hit their plan, and what closes the gap for the rest

EVOS reads the public evidence on a company (patents, filings, competitor moves) and returns the analysis an analyst team would take weeks to produce. Test a growth story in days instead of quarters.

PlaceholderVisual: portfolio grid of 6 to 8 anonymized company tiles with gap bars (green, amber, red). One tile highlighted: "Plan needs 14%. On track for 6%."

The return now depends on growth you can't see coming

Growth targets in PE plans have roughly doubled in a decade. Most portfolio reviews still look backward at reported revenue. By the time a gap shows in the numbers, the time to close it has gone.

Delay pushes the growth curve back two to four years. On a five-year hold, that is most of the value creation plan.

Placeholder: Bain chart component from rapidalpha.com, if Matthew agrees to share it across sites.

Four jobs EVOS does for a fund

Diligence

Technology and IP evidence on a target within deal timelines. See whether the growth story holds before you price it.

Watching a company you own

The gap between the growth the plan needs and the growth it's on track for, as a number and a date.

IP risk

Where the patents protecting the plan expire, who's filing around them, and what that means for revenue.

Entering a new market

A fragmented market mapped (players, financials, products) with the consolidation moves visible early.

PlaceholderMock-up: four-page report cover, fanned out

Four pages on a company you own

  • The growth gap, as a number and a date
  • Where the market is moving, and what the plan has missed
  • IP risk on the plan you've already funded
  • Whether the return still works on this timeline

Built from public information only, so nothing needs an NDA.

Secondary link "See a sample report →" only if a redacted report is approved

One view across every company you own

Each company's goal, gap and bets roll up into one picture, so you can see where to put operating attention, and which management teams need help turning a number into a plan.

PlaceholderScreenshot: the portfolio view, full width
Use case · Public data only · Roche is not an EVOS customer

We pointed the method at Roche's public record. It called the revenue mix seven years early.

Half of Roche Pharmaceuticals' revenue was heading off patent. The pipeline evidence already showed what would replace it.

Read the use case →

CHF 21.0bn → 3.2bn
the three blockbusters, 2018 to FY2025
CHF 21.4bn
five successor medicines, FY2025
7 of 10
Roche's best sellers now from the engine the data flagged

Name one company. We'll show you its gap.

Bring a company you own or are looking at. We'll run it through EVOS on public data before the demo.